Your browser doesn't support javascript.
loading
Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
Ekimov, Aleksei; Arunachalam, Arun B; Blake, Taylor; Bodle, Jesse; Couzens, Laura; Dubey, Sitara; Eichelberger, Maryna; Engelhardt, Othmar G; Gubinelli, Francesco; Joshi, Manju; Melnyk, Darya; Palladino, Giuseppe; Rigsby, Peter; Rockman, Steven; Savina, Natalya; Smith, Elena; Gilchrist, Shawn A N.
Afiliación
  • Ekimov A; Department of New Technologies, Federal State Unitary Enterprise (FSUE), Saint-Petersburg Scientific Research Institute of Vaccines and Serums (SPbSRIVS), Federal Medical-Biological Agency (FMBA) of Russia, Saint-Petersburg 198320, Russian Federation. Electronic address: a.a.ekimov@niivs.ru.
  • Arunachalam AB; Global Analytical Sciences, R&D Sanofi, 1 Discovery Dr, Swiftwater, PA 18370, USA. Electronic address: arun.arunachalam@sanofi.com.
  • Blake T; Global Analytical Sciences, R&D Sanofi, 1 Discovery Dr, Swiftwater, PA 18370, USA. Electronic address: taylor.blake@sanofi.com.
  • Bodle J; Technical Development and Global Process Innovation, Seqirus Ltd, 63 Poplar Rd, Parkville, Victoria 3052, Australia. Electronic address: Jesse.Bodle@seqirus.com.
  • Couzens L; Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America. Electronic address: laura
  • Dubey S; Standards Lifecycle, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK. Electronic address: Sitara.Dubey@nibsc.org.
  • Eichelberger M; Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America. Electronic address: maryn
  • Engelhardt OG; Vaccines, Scientific Research & Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK. Electronic address: Othmar.Engelhardt@nibsc.org.
  • Gubinelli F; Standards Lifecycle, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK. Electronic address: Francesco.Gubinelli@nibsc.org.
  • Joshi M; Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America. Electronic address: Manju
  • Melnyk D; Division of Biological Standards and Quality Control (DBSQC), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002, United States of America. Electronic address: Darya
  • Palladino G; Preclinical Research, Seqirus, 50 Hampshire Street, 9th Floor Cambridge, MA 02139, United States of America. Electronic address: Giuseppe.Palladino@Seqirus.com.
  • Rigsby P; Analytical and Biological Sciences, Scientific Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar EN6 3QG, UK. Electronic address: peter.rigsby@nibsc.org.
  • Rockman S; Technical Development and Global Process Innovation, Seqirus Ltd, 63 Poplar Rd, Parkville, Victoria 3052, Australia. Electronic address: Steve.Rockman@seqirus.com.
  • Savina N; Department of New Technologies, Federal State Unitary Enterprise (FSUE), Saint-Petersburg Scientific Research Institute of Vaccines and Serums (SPbSRIVS), Federal Medical-Biological Agency (FMBA) of Russia, Saint-Petersburg 198320, Russian Federation. Electronic address: n.n.savina@niivs.ru.
  • Smith E; Analytical CMC, Vaccine mRNA Center of Excellence, Sanofi, 200 West Street, Waltham, MA 02451, United States of America. Electronic address: elena.smith@sanofi.com.
  • Gilchrist SAN; S Gilchrist Consulting Services Inc, 8 Covebank Crescent, Brampton, ON L6P 2X5, Canada. Electronic address: shawngilchrist@sympatico.ca.
Vaccine ; 41(32): 4639-4647, 2023 07 19.
Article en En | MEDLINE | ID: mdl-37344260
ABSTRACT
Determination of the potency of a vaccine is critical to ensuring that an appropriate dose is delivered, lot-to-lot consistency is maintained, and that the formulation is stable over the life of the vaccine. The potency of inactivated influenza vaccines is determined routinely by the Single Radial Immunodiffusion (SRID) assay. A number of alternative potency assays have been proposed and have been under evaluation in recent years. The aim of this study was to compare a surface plasmon resonance-based assay and two different enzyme linked immunoassays against the current potency assay, SRID, and against mouse immunogenicity when haemagglutinin antigen of the A(H1N1)pdm09 component of an inactivated influenza vaccine is stressed by elevated temperature, low pH and freezing. This analysis demonstrated that the alternative assays had good correspondence with SRID for samples from most stress conditions and that the immunogenicity in mice corresponded with potency in SRID for all stress samples. Subject to further analysis, the assays have been shown to have the potential to possibly replace, and at least complement, SRID.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article
...